Exencial Wealth Advisors LLC Raises Holdings in Stryker Corporation $SYK

Key Points

• Exencial Wealth Advisors LLC increased its stake in Stryker by 318.6% during Q4 to 29,086 shares, valued at about $10.223 million.
• Director Ronda E. Stryker sold 250,000 shares on Feb. 4 at an average price of $362.92, realizing roughly $90.73 million and reducing her holding by 9.23%.
• Stryker beat quarterly estimates with $4.47 EPS and $7.17 billion revenue (up 11.4% YoY), declared a quarterly dividend of $0.88 ($3.52 annual, 1.1% yield), and holds a consensus analyst rating of Moderate Buy with a $421.11 price target.

Exencial Wealth Advisors LLC increased its stake in shares of Stryker Corporation (NYSE:SYK - Free Report) by 318.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 29,086 shares of the medical technology company's stock after buying an additional 22,138 shares during the quarter. Exencial Wealth Advisors LLC's holdings in Stryker were worth $10,223,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in SYK. Corient Private Wealth LLC grew its holdings in shares of Stryker by 104.4% during the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company's stock worth $887,525,000 after buying an additional 1,146,998 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Stryker by 13.3% during the third quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company's stock worth $2,342,987,000 after buying an additional 741,542 shares during the last quarter. Strive Asset Management LLC purchased a new position in shares of Stryker during the third quarter worth about $227,389,000. Credit Agricole S A purchased a new position in shares of Stryker during the third quarter worth about $194,045,000. Finally, Pictet Asset Management Holding SA grew its holdings in shares of Stryker by 190.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 466,256 shares of the medical technology company's stock worth $163,878,000 after buying an additional 305,640 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director directly owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.60% of the company's stock.

Stryker Price Performance

Shares of NYSE:SYK opened at $329.09 on Tuesday. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66. The company has a market cap of $126.04 billion, a P/E ratio of 39.18, a PEG ratio of 1.92 and a beta of 0.92. Stryker Corporation has a 52 week low of $319.32 and a 52 week high of $404.87. The company has a 50-day moving average price of $349.03 and a 200 day moving average price of $357.85.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 EPS for the quarter, beating analysts' consensus estimates of $4.40 by $0.07. The firm had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm's revenue was up 11.4% compared to the same quarter last year. During the same quarter last year, the firm earned $4.01 earnings per share. Research analysts predict that Stryker Corporation will post 14.91 earnings per share for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Stryker's dividend payout ratio (DPR) is presently 41.90%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of research reports. William Blair reissued an "outperform" rating on shares of Stryker in a report on Thursday, March 5th. The Goldman Sachs Group lowered their price target on Stryker from $403.00 to $357.00 and set a "neutral" rating on the stock in a report on Thursday, April 9th. Sanford C. Bernstein raised their price target on Stryker from $450.00 to $465.00 and gave the stock an "outperform" rating in a report on Friday, January 9th. Jefferies Financial Group restated a "buy" rating and issued a $465.00 price objective on shares of Stryker in a research report on Wednesday, March 4th. Finally, Leerink Partners began coverage on shares of Stryker in a research report on Monday, April 13th. They issued an "outperform" rating and a $410.00 price objective for the company. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $421.11.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.